Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data after the market closes on Monday, May 12th. Analysts expect Aquestive Therapeutics to post earnings of ($0.17) per share and revenue of $12.23 million for the quarter. Aquestive Therapeutics has set its FY 2025 guidance at EPS.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $11.87 million during the quarter, compared to the consensus estimate of $13.11 million. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Aquestive Therapeutics Price Performance
NASDAQ:AQST remained flat at $3.00 during trading hours on Friday. 725,187 shares of the company traded hands, compared to its average volume of 1,471,701. Aquestive Therapeutics has a 1 year low of $2.20 and a 1 year high of $5.80. The stock's fifty day moving average price is $2.78 and its 200-day moving average price is $3.55. The company has a market capitalization of $297.96 million, a PE ratio of -6.67 and a beta of 2.02.
Analyst Ratings Changes
Several equities research analysts recently weighed in on AQST shares. Alliance Global Partners reiterated a "buy" rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Wednesday, April 2nd. Lake Street Capital lowered their price objective on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, March 7th. Finally, Raymond James set a $7.00 target price on Aquestive Therapeutics in a research report on Friday, March 7th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $10.67.
Check Out Our Latest Research Report on AQST
Aquestive Therapeutics Company Profile
(
Get Free Report)
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Recommended Stories
Before you consider Aquestive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.
While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
